Nishimura M, Sugiura T, Urata A, Ota K
Gan To Kagaku Ryoho. 1985 Jan;12(1):54-60.
Advances in the treatment of inoperable non-small cell lung cancer (NSCLC) have been falling behind the recent results obtained for small cell lung cancer (SCLC) which had been considered the more malignant type with the shortest survival time. Recently, however, with the introduction of cisplatin, the results of combination chemotherapy for NSCLC have shown a degree of advancement so that an average response rate of 40% and a median survival time (MST) of 8-10 months can be obtained. Our method of combination chemotherapy, PPM (cisplatin, peplomycin, mitomycin C), resulted in an overall response rate of 44% (40% squamous, 29% adeno, 64% large) and an MST of more than 23.3 months in responders. With PFM (cisplatin, 5FU, mitomycin C), response rate was 35% and an MST of 18.7 months was obtained for adenocarcinoma responders. It can therefore be said that we have achieved a new degree of success in the treatment in NSCLC.
不可切除的非小细胞肺癌（NSCLC）的治疗进展一直落后于小细胞肺癌（SCLC）最近取得的成果，小细胞肺癌曾被认为是恶性程度更高、生存时间最短的类型。然而，最近随着顺铂的引入，NSCLC联合化疗的结果显示出一定程度的进展，平均缓解率可达40%，中位生存时间（MST）为8至10个月。我们的联合化疗方法PPM（顺铂、培洛霉素、丝裂霉素C）的总缓解率为44%（鳞状细胞癌为40%，腺癌为29%，大细胞癌为64%），缓解者的MST超过23.3个月。使用PFM（顺铂、5-氟尿嘧啶、丝裂霉素C）时，腺癌缓解者的缓解率为35%，MST为18.7个月。因此，可以说我们在NSCLC治疗方面取得了新的成功。
